Objectives: To determine the association between the severity of premenstrual (PMS) symptoms and headache outcome measures during natural menstrual cycles and after medical oophorectomy.
Background: Premenstrual syndrome may occur in 64% of those with pure menstrual migraine and 33% of those with menstrually related migraine. Few past studies have examined the relationship between the severity of PMS symptoms and migraine headache.
Methods: Data were obtained from a 6.5-month randomized-controlled trial examining the role of medical oophorectomy in the prevention of migraine headache and later divided into two data sets for analysis purposes. The menstrual cycle data set was composed of data from three natural menstrual cycles obtained from 21 participants during lead-in and placebo run-in phases. Each menstrual cycle was subdivided into seven 3-day intervals based on urine hormone metabolites. The medical oophorectomy data set included data from a 2-month treatment period in which a medical oophorectomy was induced by gonadotropin-releasing hormone agonists (GnRHa) and participants were randomized to transdermal estradiol or a matching placebo (GnRHa/estradiol and GnRHa/placebo groups, respectively). All participants completed a daily diary recording the severity of PMS symptoms and headache outcome measures. The primary outcome measures were the PMS index (mean of the daily PMS severity scores) and the headache index (mean of the headache severity scores). Pearson correlation coefficients were used to assess the degree of association between the outcome measures.
Results: Menstrual Cycle Data Set.-The PMS index was significantly correlated with the headache index during native menstrual cycles (correlation coefficient of 0.47; P < .05) and during all seven intervals of the menstrual cycle (correlation coefficients of 0.39 to 0.65; all P values < .05). Medical Oophorectomy Data Set.-Correlation coefficients between the PMS and headache indices were 0.58 and 0.47 for the GnRHa/estradiol (n = 9) and GnRHa/placebo groups, respectively (P-values of <.05).
Conclusions: Moderate correlations exist within female migraineurs between the severity of PMS symptoms and headache outcome measures throughout natural menstrual cycles as well as after medical oophorectomy. Our data would suggest that the presence and severity of headache might modulate PMS symptoms in female migraineurs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1526-4610.2006.00306.x | DOI Listing |
Alzheimers Dement
December 2024
Northeast Ohio Medical University, Rootstown, OH, USA.
Background: Integrins are essential mediators of numerous critical cellular processes. Increasing evidence indicates that aberrant function of αVβ1 integrins contributes to the onset and progression of tauopathy. Previously, our group showed that the neuroprotective exercise hormone irisin-a known αVβ integrin modulator, prevented age-related increases in phosphorylated tau and inflammation in hippocampus of presymptomatic-age female but not male htau tauopathy-model mice (Bretland et al.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Albany Medical College, Albany, NY, USA.
Background: About two-thirds of those with Alzheimer's disease (AD) are women, most of whom are post-menopausal. Menopause accelerates the risk for dementia by increasing the risk for metabolic, cardiovascular, and cerebrovascular diseases. Mid-life metabolic disease (e.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Background: Endogenous estrogen history across the life course may be associated with better cognitive maintenance. Few large longitudinal studies have evaluated this prospectively, and results have been inconsistent. We assessed the association of reproductive span, an indicator of endogenous estrogen history, with cognitive change in older women.
View Article and Find Full Text PDFPathologica
October 2024
Pathology Unit, Department of Oncology, ASST Sette Laghi, Varese, Italy.
P53-abnormal endometrial carcinomas are high-grade and aggressive tumors which should be treated with chemo-/radiotherapy. In low-grade endometrioid carcinoma (LGEC), abnormal expression of p53 is an exceptional finding and is typically accompanied by patchy p16 positivity and diffuse hormone receptor expression. Herein, we report a case of LGEC exhibiting both p53 and p16 overexpression, highlighting the diagnostic pitfalls related to such phenotype.
View Article and Find Full Text PDFObstet Gynecol
January 2025
Federal University of Mato Grosso, Sinop, Mato Grosso, Sciences Medical School of Santos, Santos, Santa Marcelina College of Medicine, São Paulo, and Dante Pazzanese Institute of Cardiology, São Paulo, São Paulo, Feevale University, Novo Hamburgo, Rio Grande do Sul, Santo Agostinho Faculty, Vitória da Conquista, Bahia, and Federal University of Pará, Belém, Pará, Brazil.
Objective: To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women.
Data Sources: MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!